ATL’s Fill joins pharmaceutical start-up

Article

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new pharmaceutical company based in Kirkland, WA. Effective March 1, he replaced Cytran’s former CEO, Philip Syrdal. Fill served as CEO of Bothell, WA-based ATL from 1987 through December 1998. Cytran was founded in 1991 and develops peptide compounds for the treatment of cancer and modulation of the immune system.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.